Roche's Wilserdly (giredestrant) has been approved by the US Food and Drug Administration, taken with everolimus, for adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer that has worsened after hormone therapy. Roche announced the decision on 16 November 2026. The pill is not approved in the EU, and its pivotal trial had no Irish sites.
In the phase III evERA trial, the combination cut the risk of disease progression or death by 62% compared with standard hormone therapy plus everolimus. A second FDA decision, on giredestrant after surgery for early breast cancer, is due by 30 November 2026. That early breast cancer trial, lidERA, enrolled patients at seven Irish hospitals.
- Decision: FDA approval of Wilserdly (giredestrant) with everolimus, announced by Roche and Genentech on 16 November 2026.
- Who it covers: adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that recurred during or after adjuvant hormone therapy, or progressed on at least one hormone-based regimen for advanced disease.
- Evidence: evERA, a phase III trial of 373 patients. In the 207 with ESR1 mutations, the hazard ratio for progression or death was 0.38, and median progression-free survival was 10 months against 5.5 months.
- Next decision: the FDA has a Prescription Drug User Fee Act date of 30 November 2026 for adjuvant use in stage I to III early breast cancer, based on lidERA.
- Ireland and the EU: no EU authorisation or EMA opinion has been published. lidERA listed seven Irish sites; evERA listed none.
What has the FDA approved?
Roche's release says Wilserdly is approved in combination with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, with the mutation detected by an FDA-authorised test. The disease must have recurred during or after adjuvant hormone (endocrine) therapy, or progressed on at least one endocrine-based regimen in the metastatic setting.
The recommended dose of giredestrant is 30 mg by mouth once a day, with or without food, according to CancerNetwork's report of the FDA label. The FDA also authorised FoundationOne Liquid CDx, a blood test, to find patients with ESR1 mutations. Genentech says Wilserdly is expected to be available in the US "in the coming weeks". No list price was disclosed.
Everolimus is a tablet that blocks mTOR, a growth signal inside cancer cells that tumours can use to escape hormone therapy. Roche describes the new regimen as combining an oestrogen receptor blocker with an mTOR inhibitor to tackle this resistance route. Our compound pages on giredestrant and everolimus list current trials for both.
What are ESR1 mutations and why do they matter?
Most breast cancers are fuelled by oestrogen and are treated for years with hormone therapy such as aromatase inhibitors or tamoxifen. The ESR1 gene carries the instructions for the oestrogen receptor itself. Under the pressure of treatment, some tumours acquire ESR1 mutations that keep the receptor switched on even when oestrogen levels are low, so standard hormone therapy stops working.
Genentech's release describes ESR1 mutations as "the primary cause of hormone therapy resistance" and says they affect up to 40% of patients with hormone receptor-positive metastatic breast cancer. Because the mutation develops over time, it is usually found by testing a blood sample for tumour DNA after the cancer has progressed, which is why the approval comes with a companion test.
What did the evERA trial show?
evERA (NCT05306340) randomised 373 patients whose cancer had progressed after earlier hormone therapy. Patients took either giredestrant plus everolimus or the doctor's choice of standard hormone therapy plus everolimus. Roche says the results are published in the New England Journal of Medicine.
| Measure | Result |
|---|---|
| Patients with ESR1 mutations | 207 of 373 enrolled (102 giredestrant arm, 105 control arm) |
| Median progression-free survival | 10 months with giredestrant plus everolimus vs 5.5 months with standard hormone therapy plus everolimus |
| Hazard ratio for progression or death | 0.38 (95% CI 0.27 to 0.54; p<0.0001), a 62% lower risk |
| Objective response rate | 27% vs 14% |
| Overall population (all 373 patients) | Median progression-free survival 8.8 vs 5.5 months (HR 0.56) |
| Overall survival | Immature at the time of analysis |
The most common side effects reported with the combination were mouth sores (stomatitis), rash, tiredness, diarrhoea, muscle and joint pain, lung inflammation (pneumonitis) and nausea. The label warns about a slow heart rate (bradycardia) and harm to an unborn baby, according to CancerNetwork and Genentech.
Dr Erica L. Mayer of the Dana-Farber Cancer Institute, quoted by Roche, said the regimen "directly targets the primary genomic drivers of resistance." Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said "the development of resistance to endocrine therapy remains a substantial challenge." Teresa Graham, Chief Executive Officer of Roche Pharmaceuticals, called the approval a "pivotal leap forward".
How does Wilserdly compare with other oral SERDs?
Giredestrant is a selective oestrogen receptor degrader, or SERD: it blocks the oestrogen receptor and marks it for destruction. Giredestrant joins a small group of SERDs taken as tablets.
Elacestrant (Orserdu, authorised to Stemline Therapeutics) received EU authorisation on 15 September 2023 as a single medicine for postmenopausal women and men whose ER-positive, HER2-negative advanced breast cancer has an activating ESR1 mutation and has progressed after hormone therapy including a CDK 4/6 inhibitor. Imlunestrant (Inluriyo, from Eli Lilly) was approved by the FDA on 25 September 2025 for ESR1-mutated advanced disease, based on the EMBER-3 trial. Wilserdly differs in being approved as a combination with everolimus, and in having a pending filing in early breast cancer. Our page on elacestrant lists its trials.
What would an adjuvant approval mean?
Adjuvant treatment is given after surgery to lower the chance of the cancer returning. Roche says it filed giredestrant for adults with stage I to III ER-positive, HER2-negative early breast cancer at intermediate to high risk of recurrence. The FDA accepted the application under Priority Review with a decision date of 30 November 2026. Roche says that, if approved, it would be the first new adjuvant hormone therapy in more than 20 years.
The filing rests on lidERA (NCT04961996), which enrolled 4,170 patients. At the primary analysis presented at the 2025 San Antonio Breast Cancer Symposium, giredestrant lowered the risk of invasive disease recurrence or death by 30% against standard hormone therapy (HR 0.70, 95% CI 0.57 to 0.87). At three years, 92.4% of patients on giredestrant were alive and free of invasive disease, against 89.6% on tamoxifen or an aromatase inhibitor, CancerNetwork reported. This is a far larger patient group than the ESR1-mutated advanced setting.
Did the trials run in Ireland?
Not evERA. Its ClinicalTrials.gov record lists 136 sites in 13 countries, including Spain, Italy, Germany, Greece and four in the United Kingdom, but none in Ireland.
lidERA did include Ireland. Its record lists seven Irish sites: Cork University Hospital, Bon Secours Hospital Cork, St Vincent's University Hospital and Beaumont Hospital in Dublin, Galway University Hospital, Mid-Western Regional Hospital Limerick and Waterford Regional Hospital, as named in the record. The trial is active but no longer recruiting. A smaller phase II study in premenopausal women, PREcoopERA (NCT05896566), listed St James's Hospital in Dublin and University Hospital Galway and is marked completed. Our list of breast cancer trials in Ireland shows current studies.
When could giredestrant reach patients in Ireland?
That is not known. Roche and Genentech say only that "additional regulatory filings and development activities are underway" outside the US. Neither release names the EU, and we found no EMA product page, opinion or published validation for giredestrant. Any EU approval would come through the European Commission after a CHMP opinion.
After that, the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics (NCPE). The NCPE site shows no entry for giredestrant. It does show the route an oral SERD takes: for elacestrant, the NCPE completed a rapid review on 22 October 2026 and recommended a full health technology assessment, which the HSE commissioned on 23 October 2026. The NCPE lists that assessment as at the pre-submission consultation stage.
In Ireland, Roche's medicines business trades as Roche Products (Ireland) Limited. The group's former pharmaceutical plant at Clarecastle, Co Clare, ceased operations in March 2020, according to roche.ie. Patients should not change treatment without speaking to their oncology team.
Frequently asked questions
What is Wilserdly?
Wilserdly is the brand name of giredestrant, a once-daily oral selective oestrogen receptor degrader from Roche and its US unit Genentech.
Who is it approved for in the US?
Adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that has progressed after hormone therapy, taken together with everolimus.
How is ESR1 tested?
With an FDA-authorised test. The FDA authorised the FoundationOne Liquid CDx blood test as a companion diagnostic alongside the approval.
Is giredestrant approved in the EU or Ireland?
No. No EU authorisation or EMA opinion has been published, and the NCPE lists no assessment.
When is the decision on early breast cancer?
The FDA's decision date for adjuvant use, based on the lidERA trial, is 30 November 2026.
Outlook
The next milestone is the FDA's adjuvant decision by 30 November, which would take giredestrant from a niche resistance setting into routine care after surgery. For Ireland, the questions are when Roche files in the EU and whether the lidERA data, generated partly at seven Irish hospitals, lead to an NCPE assessment. Priya Life Science will report when an EMA or NCPE entry appears.
Sources
- Roche, FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer, 16 November 2026
- Genentech, FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, 16 November 2026
- CancerNetwork, FDA approves giredestrant plus everolimus for ER+/HER2-, ESR1-mutated breast cancer, 16 November 2026
- OncLive, FDA approves giredestrant plus everolimus for ER+/HER2-, ESR1-mutated metastatic breast cancer, 16 November 2026
- CancerNetwork, Adjuvant giredestrant improves invasive DFS in ER+/HER2- early breast cancer, 30 May 2026
- ClinicalTrials.gov, evERA Breast Cancer, NCT05306340, accessed 18 November 2026
- ClinicalTrials.gov, lidERA Breast Cancer, NCT04961996, accessed 18 November 2026
- ClinicalTrials.gov, PREcoopERA, NCT05896566, accessed 18 November 2026
- European Medicines Agency, Orserdu (elacestrant): EPAR, accessed 18 November 2026
- US Food and Drug Administration, FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, 25 September 2025
- National Centre for Pharmacoeconomics, Elacestrant (Orserdu). HTA ID: 26053, accessed 18 November 2026
- Roche Ireland, About Roche in Ireland, accessed 18 November 2026
Cover image: AI-generated illustration.